EXEL Climbing Ahead of FDA Decision

EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one!

fool.com/investing/general/2012/11/25/2-important-decisions-to-watch-for-this-week-in-th.aspx